🏠

AI Startup Surge 🚀: Wang's $200M Vision! ✨

July 15, 2026 | Author

Tech

🎧 Audio Summaries
English flag
French flag
German flag
Japanese flag
Korean flag
Mandarin flag
Spanish flag
🛒 Shop on Amazon

🧠Quick Intel


  • Miles Wang is departing OpenAI to found Chai Discovery, an AI model development startup.
  • Wang is in discussions to raise $200 million at a $2 billion valuation, with Lightspeed leading the investment.
  • Chai Discovery, Wang’s startup, previously raised $400 million at a $3.8 billion valuation.
  • Josh Meier, a co-founder of Chai Discovery, previously worked as a researcher at OpenAI.
  • Google DeepMind spinout, Isomorphic Labs, recently secured a $2.1 billion Series B funding round in May.
  • Wang joined OpenAI in 2024 after completing his bachelor’s degree in computer science at Harvard.

    • 📝Summary


    Miles Wang, formerly an OpenAI researcher, is departing the company to pursue a new venture in artificial intelligence for drug discovery. He’s currently in discussions to secure approximately $200 million in funding at a $2 billion valuation, spearheaded by Lightspeed. This follows a recent $400 million raise for Chai Discovery, a two-year-old startup, and the prior experience of co-founder Josh Meier at OpenAI. The move reflects a broader trend of AI talent shifting towards specialized applications, mirroring similar investments by Isomorphic Labs and highlighting the growing interest in accelerating scientific breakthroughs.

    💡Insights

    ▼


    THE RISE OF CHAI DISCOVERY
    Miles Wang, a prominent OpenAI researcher known for his pioneering work in applying artificial intelligence to accelerate scientific and biological breakthroughs, is embarking on a new venture. Wang’s departure from ChatGPT’s parent company signals a growing trend within the tech industry – a renewed focus on leveraging AI to revolutionize drug discovery. This initiative, spearheaded by Chai Discovery, aims to develop sophisticated AI models capable of predicting molecular interactions, ultimately leading to the identification of novel drug candidates. The company’s genesis is intertwined with OpenAI, as co-founder Josh Meier previously held a research position there, demonstrating a shared commitment to pushing the boundaries of AI-driven scientific exploration.

    INVESTOR CONFIDENCE AND VALUATION
    The burgeoning interest in AI-driven drug discovery is reflected in substantial investment rounds secured by Chai Discovery and other prominent players in the field. Just last week, Chai Discovery announced a $400 million Series A funding round, achieving a valuation of $3.8 billion. This influx of capital underscores investor confidence in the potential of AI to dramatically shorten drug development timelines and improve success rates. Furthermore, the activity of Isomorphic Labs, a Google DeepMind spinout also focused on AI-powered drug discovery, with a recent $2.1 billion Series B, highlights the broader market trend. These significant investments, alongside ongoing discussions regarding a potential $200 million investment for Wang’s new company at a $2 billion valuation, point to a substantial appetite for innovation within the life sciences sector. Lightspeed is currently in discussions to lead this funding round, although details remain subject to change.

    WANG’S VISION: REIMAGINING EXISTING MEDICATIONS
    At the core of Wang’s new venture lies a strategic focus on identifying previously untapped applications for existing FDA-approved drugs. This approach offers a compelling advantage over developing entirely new medications – the accelerated timeline associated with repurposing established drugs, which have already undergone rigorous safety testing. Wang’s background at OpenAI, where he collaborated on research evaluating AI’s role in automating and accelerating scientific discovery, provides a strong foundation for this endeavor. His decision to leave Harvard, where he was pursuing a bachelor’s degree in computer science, reflects a broader trend of investors embracing young, ambitious founders regardless of their formal educational background. Ultimately, Wang’s goal is to harness the power of AI to unlock new therapeutic possibilities, transforming the way drugs are developed and utilized.

    Related Articles